Fig. 3

Analysis of sustained CID events overall and by individual components over 24 weeks (ITT population). *p < 0.05, **p < 0.01, ***p < 0.001 HR vs placebo. The risk of a sustained CID event was analyzed using a Cox-Proportional Hazard model including study, treatment group, and smoking status as covariates. AB, aclidinium bromide; CID, clinically important deterioration; FEV₁, forced expiratory volume in 1 second; FF, formoterol fumarate; HR, hazard ratio; ITT, intent-to-treat; SGRQ, St George’s Respiratory Questionnaire; TDI, Transition Dyspnea Index